Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.
Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21287, USA.
Int J Environ Res Public Health. 2020 Nov 17;17(22):8502. doi: 10.3390/ijerph17228502.
(1) : Monthly variability in smoking behaviors in caregivers of pediatric asthmatics yields questions of how much and when does smoking reduction result in improved environmental and clinical outcomes. (2) : Post hoc analysis of data from a 6 month pilot randomized-control trial occurring from May 2017 to May 2018 in Baltimore City (MD, USA). The initial trial's primary intervention explored the utility of financial incentives in modifying caregiver smoking behaviors. Post hoc analyses examined all dyads independent of the initial trial's randomization status. All caregivers received pediatric tobacco smoke harm reduction education, in addition to monthly encouragement to access the state tobacco quitline for individual phone-based counseling and nicotine replacement therapy. Maternal caregivers who were active cigarette smokers and their linked asthmatic child (aged 2-12 years) were grouped into two classifications ("high" versus "low") based on the child and caregiver's cotinine levels. A "low" cotinine level was designated by at least a 25% reduction in cotinine levels during 3 months of the trial period; achieving ≤2 months of low cotinine levels defaulted to the "high" category. Twenty-seven dyads (caregivers and children) (total = 54) were assigned to the "high" category, and eighteen dyads (caregivers and children) (total = 36) were allocated to the "low" category. The primary outcome measure was the correlation of caregiver cotinine levels with pediatric cotinine values. Secondary outcomes included asthma control, in addition to caregiver anxiety and depression. (3) : Caregivers with 3 months of ≥25% decrease in cotinine levels had a significantly greater mean change in child cotinine levels ( = 0.018). "Low" caregiver cotinine levels did not significantly improve pediatric asthma control (OR 2.12 (95% CI: 0.62-7.25)). Caregiver anxiety and depression outcomes, measured by Patient Health Questionnaire (PHQ)-4 scores, was not significantly different based on cotinine categorization ( = 0.079); (4) : Reduced pediatric cotinine levels were seen in caregivers who reduced their smoking for at least 3 months, but clinical outcome measures remained unchanged.
(1) :儿科哮喘患儿照顾者的吸烟行为每月变化,引发了这样的问题,即减少吸烟量和时间会在多大程度上改善环境和临床结果。
(2) :这是对 2017 年 5 月至 2018 年 5 月在美国马里兰州巴尔的摩市进行的一项为期 6 个月的试点随机对照试验(RCT)数据的事后分析。该初始试验的主要干预措施是探讨经济激励措施在改变照顾者吸烟行为方面的效用。事后分析独立于初始试验的随机分组状态检查了所有对子。所有照顾者都接受了儿科烟草烟雾减少危害教育,此外,每月还鼓励他们访问州烟草戒烟热线,以获得个人电话咨询和尼古丁替代疗法。主动吸烟的母亲照顾者及其相关的哮喘儿童(年龄 2-12 岁)根据儿童和照顾者的可替宁水平分为两类(“高”与“低”)。如果在试验期间的 3 个月内,可替宁水平至少降低 25%,则指定为“低”可替宁水平;如果可替宁水平在 2 个月内持续降低,则默认归类为“高”类别。27 对(照顾者和儿童)(总计=54)被分配到“高”类别,18 对(照顾者和儿童)(总计=36)被分配到“低”类别。主要结局测量指标是照顾者可替宁水平与儿科可替宁值的相关性。次要结局包括哮喘控制,以及照顾者焦虑和抑郁。
(3) :可替宁水平降低至少 3 个月的照顾者,其儿童可替宁水平的平均变化显著更大(=0.018)。“低”可替宁水平的照顾者并不能显著改善儿科哮喘控制(比值比 2.12(95%置信区间:0.62-7.25))。通过患者健康问卷(PHQ-4)评分测量的照顾者焦虑和抑郁结局,根据可替宁分类没有显著差异(=0.079)。
(4) :至少减少吸烟 3 个月的照顾者,其儿科可替宁水平降低,但临床结局测量仍未改变。